FDA appoints psychedelic proponent as CDER deputy director as the top role remains open

FDA names a psychedelic proponent as CDER deputy director, signaling continued attention to how psychedelic medicines may be evaluated and regulated. The appointment comes while the top CDER leadership role remains open, highlighting an ongoing transition in the agency's drug evaluation structure. The news framing centers on organizational decision making inside the FDA's Center for Drug Evaluation and Research, with the deputy director role positioned as a key leadership post during the broader push to develop and oversee novel therapeutics.